De novo patients with high-volume metastatic hormone-sensitive prostate cancer can benefit from the addition of docetaxel to triplet therapy: Network-analysis and systematic review by Hanxu Guo, Chengqi Jin, Li Ding, Jun Xie, Jing Xu, Ruiliang Wang, Hong Wang, Changcheng Guo, Jiansheng Zhang, Bo Peng, Xudong Yao, Jing Yuan, Bin Yang, Sihan Zhou

Get full text